All content for This Week in Addiction Medicine from ASAM is the property of American Society of Addiction Medicine and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
A podcast source for news briefings on the top stories in the field of addiction medicine.
Lead: Injectable-Only Overlapping Buprenorphine Starting Protocol in a Low-Threshold Setting
This Week in Addiction Medicine from ASAM
7 minutes
2 months ago
Lead: Injectable-Only Overlapping Buprenorphine Starting Protocol in a Low-Threshold Setting
Injectable-Only Overlapping Buprenorphine Starting Protocol in a Low-Threshold Setting
JAMA Network Open
Injectable-only buprenorphine protocols are an exciting new strategy for buprenorphine initiation, particularly in the fentanyl era. This is a cohort study of 95 patients with moderate to severe opioid use disorder who received care in a low-threshold setting in Seattle. 79% of patients included in the study were experiencing homelessness or living in permanent supportive housing. Patients selected a long-acting injectable (LAI) buprenorphine initiation protocol which included three escalating doses of LAI buprenorphine over three days, with no sublingual buprenorphine and without cessation of fentanyl/opioid use. 75% of the patients completed the protocol, and 64% received a second monthly dose of LAI buprenorphine.
Read this issue of the ASAM Weekly
Subscribe to the ASAM Weekly
Visit ASAM
This Week in Addiction Medicine from ASAM
A podcast source for news briefings on the top stories in the field of addiction medicine.